Patient-derived brain organoids suggest vitamin B3 derivative may help rare childhood neurodegenerative disease

Research into the rare childhood neurodegenerative disorder DHDDS-related disease has produced a new lead worth following. According to conference news released by the European Society of Human Genetics and EurekAlert, researchers used patient-derived “mini-brain” organoids to reproduce some disease features and found that the vitamin B3 derivative nicotinamide mononucleotide (NMN) may have potential to slow disease progression.

DHDDS-related disease is a rare neurodegenerative disorder caused by variants in the DHDDS gene and usually leads to severe neurological deterioration during childhood. Because the number of patients is small and disease progression is complex, conventional cell or animal models may not fully reflect human brain development and degeneration, making treatment development especially difficult.

At the core of this study was reprogramming patient cells and culturing them into brain organoids. These three-dimensional cell models are not equivalent to a real brain, but they can present some features of human brain tissue development and cellular interaction in the laboratory, so they are often used to study neurological diseases that are difficult to sample directly.

According to the conference release, DHDDS patient-derived organoids showed disease-related abnormal changes, allowing the research team to examine cellular pathways that may be affected. After further testing, the researchers proposed that NMN may improve some pathological manifestations and therefore became a candidate intervention direction.

NMN is a molecule related to vitamin B3 metabolism and is often discussed in the context of cellular energy metabolism and NAD+ biosynthesis pathways. However, improvement signals observed in organoids do not mean that it has been proven to treat DHDDS-related disease; dosage, long-term safety, and whether it is consistently effective across different patient genotypes all require more rigorous human data.

Notably, the release materials stated that this work has already led to early patient use and advanced an international trial. However, the publicly available abstract has not provided the full trial design, number of participants, control method, or efficacy endpoints, so it should still be viewed as an early case of moving from a patient model to clinical validation, rather than an established therapeutic breakthrough.

The study also highlights the role of organoids in rare disease research: they may shorten the distance from gene discovery to testing candidate treatments, especially for diseases with few patients where large-scale preliminary studies cannot be conducted. But organoids still have limitations, including maturity and insufficient vascular and immune environments, and their ultimate clinical value still depends on results from well-designed trials.

In the absence of other credible external sources from the same meeting that can be used for cross-checking, this news should be interpreted cautiously. It offers a biologically plausible research path: using patient cell models to reveal mechanisms, then bringing candidate molecules into clinical evaluation. Whether NMN can truly change the course of DHDDS-related disease still needs to be answered by subsequent public data.